Skip to content
Gadoxetate
Eovist (gadoxetate) is a small molecule pharmaceutical. Gadoxetate was first approved as Eovist on 2008-07-03.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Eovist
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Gadoxetate disodium
Tradename
Company
Number
Date
Products
EOVISTBayerN-022090 RX2008-07-03
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
eovistNew Drug Application2021-04-26
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
V: Various drug classes in atc
— V08: Contrast media
— V08C: Magnetic resonance imaging contrast media
— V08CA: Paramagnetic contrast media
— V08CA10: Gadoxetic acid
HCPCS
Code
Description
A9581
Injection, gadoxetate disodium, 1 ml
Clinical
Clinical Trials
16 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Ovarian neoplasmsD010051EFO_0003893C56———1—1
Congenital heart defectsD006330HP_0001627Q24.9———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Intracranial arteriosclerosisD002537EFO_1000860I67.2——1——1
Peripheral vascular diseasesD016491EFO_0003875I73.9——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C80—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AtherosclerosisD050197EFO_0003914I25.11———12
Intermittent claudicationD007383EFO_0003876I73.91———12
Peripheral arterial diseaseD058729EFO_00042651————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C50————22
Prostatic neoplasmsD011471C61————11
Rectal neoplasmsD012004————11
Magnetic resonance imagingD008279————11
Neoplasm stagingD009367————11
Healthy volunteers/patients—————11
Pulmonary embolismD011655EFO_0003827I26————11
Nephrogenic fibrosing dermopathyD054989EFO_1001814————11
Coronary artery diseaseD003324I25.1————11
Stable anginaD060050I20.8————11
Show 1 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameGADOXETATE
INNgadoxetic acid
Description
Gadoxetic acid is a gadolinium-based MRI contrast agent. Its salt, gadoxetate disodium, is marketed as Primovist in Europe and Eovist in the United States by Bayer HealthCare Pharmaceuticals.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCOc1ccc(C[C@@H](CN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])N(CC(=O)[O-])CC(=O)[O-])cc1.[Gd+3].[H+].[H+]
Identifiers
PDB—
CAS-ID135326-11-3
RxCUI802624
ChEMBL IDCHEMBL1201768
ChEBI ID—
PubChem CID25203894
DrugBankDB08884
UNII ID3QJA87N40S (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 3,405 documents
View more details
Safety
Black-box Warning
Black-box warning for: Eovist
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
48 adverse events reported
View more details